REGENXBIO to Host Conference Call on November 2 to Discuss Third Quarter 2021 Financial Results and Recent Operational Highlights
REGENXBIO Inc. (Nasdaq: RGNX) announced a conference call scheduled for November 2, 2021, at 4:30 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
REGENXBIO Inc. (Nasdaq: RGNX) announced a conference call scheduled for November 2, 2021, at 4:30 p.m. ET. The call will cover the company's financial results for the quarter ended September 30, 2021, and recent operational highlights. Investors can access the call via phone or a webcast on the REGENXBIO website. The company is focused on gene therapy through its NAV® Technology Platform, which includes over 100 exclusive AAV vectors aimed at various therapeutic areas.
Details
News Market Reaction – RGNX
The recorded move for RGNX in the trading session of this news was -2.11%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ROCKVILLE, Md., Oct. 26, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Tuesday, November 2, 2021, at 4:30 p.m. ET to discuss its financial results for the quarter ended September 30, 2021, and recent operational highlights.
To access the live call by phone, dial (855) 422-8964 (domestic) or (210) 229-8819 (international) and enter the passcode 7878814. To access a live or recorded webcast of the call, please visit the Investors section of the REGENXBIO website at www.regenxbio.com. The recorded webcast will be available for approximately 30 days following the call.
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.
Contacts:
Tricia Truehart
Investor Relations and Corporate Communications
347-926-7709
ttruehart@regenxbio.com
Investors:
Brendan Burns, 212-600-1902
brendan@argotpartners.com
Media:
David Rosen, 212-600-1902
david.rosen@argotpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-host-conference-call-on-november-2-to-discuss-third-quarter-2021-financial-results-and-recent-operational-highlights-301407609.html
SOURCE REGENXBIO Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.